Subscriber Content Read Preview
In hundreds of documented cases, cancer samples that were supposed to be one type of tumor have turned out to be another, through either careless laboratory handling, mislabeling or other mistakes.
Subscriber Content Read Preview
The FDA warned more than 50 doctors and medical practices in the U.S. that they may have bought a fake version of the cancer drug Avastin.
Subscriber Content Read Preview
Advisers to the European drug regulator recommended approval of an experimental diabetes drug that was rejected by U.S. regulators. The drug's co-developers are Bristol-Myers Squibb and AstraZeneca.
Subscriber Content Read Preview
GlaxoSmithKline said it has sold the bulk of the over-the-counter medicines it started divesting last year but hasn't yet sold the diet pill Alli.
Subscriber Content Read Preview
Europe's drug regulator requested stronger safety warnings for Novartis's Gilenya after it concluded a review of the multiple-sclerosis pill, prompted by reports of heart problems and the death of a patient.
Subscriber Content Read Preview
Subscriber Content Read Preview
Subscriber Content Read Preview
Subscriber Content Read Preview
Subscriber Content Read Preview
View an interactive map that shows you how stocks in the Pharmaceuticals & Biotech sector are doing today, at a glance.
Get in-depth research on Pharmaceuticals & Biotech companies, including complete news and financials, earnings estimates and more.
Ask a question about anything you choose, and let readers from the Journal Community answer it.
Hello
Your question to the Journal Community Your comments on articles will show your real name and not a username.Why?
Create a Journal Community profile to avoid this message in the future. (As a member you agree to use your real name when participating in the Journal Community)